Section Arrow
Quote
NUVB.NYSE
- Nuvation Bio
Quotes are at least 15-min delayed:2025/06/02 15:23 EDT
Last
 2.345
+0.225 (+10.61%)
Day High 
2.375 
Prev. Close
2.12 
1-M High
2.54 
Volume 
5.77M 
Bid
2.34
Ask
2.35
Day Low
2.16 
Open
2.17 
1-M Low
1.98 
Market Cap 
721.36M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 2.21 
20-SMA 2.2 
50-SMA 2.04 
52-W High 3.97 
52-W Low 1.54 
Exchange NYSE 
Valuation Estimation
EPS (Current/Estimated)
-2.20/-0.50
Enterprise Value
722.33M
Balance Sheet
Book Value Per Share
1.23
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
7.87M
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
OGENOragenics0.173699+0.053699+44.75%-- 
PSTVPlus Therapeutics0.3968+0.1099+38.31%-- 
PCSAProcessa Pharmaceuticals0.2965+0.004+1.37%-- 
BPMCBlueprint Medicines Corp127.565+26.215+25.87%-- 
NCNANuCana plc0.0377+0.0024+6.80%-- 
Quotes are at least 15-min delayed：2025/06/02 15:23 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.